Calcineurin inhibitor (CNI) therapy after lung transplantation increases risk of kidney failure. Early everolimus-based quadruple low CNI immunosuppression may improve renal function without compromising efficacy or safety. A prospective, randomized, open-label, 12-month multicenter trial was conducted at 8 German sites. Patients 3-18 months after lung transplantation were randomized (1:1), stratified by baseline estimated glomerular filtration rate (eGFR). In the quadruple low CNI regimen, patients received everolimus (target trough level 3-5 ng/mL) with reduced CNI (tacrolimus 3-5 ng/mL or cyclosporine 25-75 ng/mL) and a cell cycle inhibitor plus prednisone.
| INTRODUC TI ON
The number of lung transplants has been rising steadily over the past decades. 1 Advances in donor management and preservation methods have expanded the donor pool and, increasingly, elderly patients with comorbidities are undergoing transplantation. 1, 2 Long-term outcomes, however, remain inferior compared to other forms of solid organ transplantation. Fifty-six percent of lung transplant recipients survive more than 5 years, 1 with chronic lung allograft dysfunction (CLAD) and infections being the leading causes of death.
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Lung transplant recipients are at high risk of graft rejection, necessitating a more intensive immunosuppressive therapy relative to other solid organ transplants. 3 Maintenance therapy typically consists of a calcineurin inhibitor (CNI), a cell cycle inhibitor, and corticosteroids. 4 Chronic CNI therapy, however, is frequently associated with nephrotoxicity 5 and is an independent predictor for a decline in glomerular filtration rate (GFR) after lung transplantation. 6 This effect is dose dependent. 7, 8 End-stage kidney disease including the need for renal transplantation affects almost 5% of the recipients within the first 5 years. End-stage kidney disease adversely affects mortality. In large epidemiological studies, an estimated glomerular filtration rate (eGFR) <60 mL/ min per 1.73 m 2 was independently associated with higher rates of cardiovascular deaths, overall mortality, and hospitalizations. 10, 11 These effects were more pronounced in patients with lower GFR.
Maintaining immunosuppressive efficacy and preserving longterm renal function has prompted interest in the use of mammalian target of rapamycin (mTOR) inhibitors to minimize CNI exposure.
Additionally, consistent with evidence from renal 12, 13 and heart 14 transplantation, the risk of cytomegalovirus (CMV) infections is reduced in lung transplant patients receiving an mTOR inhibitor-based immunosuppressive protocol. [15] [16] [17] Everolimus in conjunction with reduced-exposure CNI therapy maintains immunosuppressive efficacy in de novo renal, 18 liver, 19 and heart 20 transplant patients. In lung transplantation, 2 randomized trials of everolimus with reduced CNI exposure, initiated early posttransplant, have shown a lower rate of acute rejection than standard CNI-based triple therapy in comparison to mycophenolic acid (MPA) formulations without affecting the incidence of CLAD. 15, 21 In terms of renal function, de novo use of everolimus with moderately reduced CNI exposure does not appear to influence posttransplant renal deterioration after lung transplantation. 15, 21 In contrast, a moderate improvement in renal function was observed in long-term thoracic transplant recipients, including lung transplanted patients, who were switched to add-on everolimus with low-dose CNI therapy late after transplantation. 22, 23 The aim of the current study was to demonstrate that everolimus with low CNI exposure in a quadruple immunosuppression regimen is superior to a standard triple CNI regimen in terms of renal function,
as assessed by eGFR, in patients with impaired kidney function early after lung transplantation. The study included patients with mild-tomoderate impairment of kidney function and excluded those with severe impairment in whom an improvement in function was less likely. after lung transplantation to a regimen of everolimus with reduced CNI exposure (quadruple low CNI) or to standard CNI therapy (standard triple CNI). All patients in both groups received a cell cycle inhibitor and steroids. The study design is summarized in Figure 1 .
| ME THODS

| Study design and conduct
54.6 mL/min for the standard triple group (least squares mean, analysis of covariance; P < .001). Key efficacy parameters (biopsy-proven acute rejection, chronic lung allograft dysfunction, and death) and safety endpoints were similar between both groups.
Quadruple low CNI immunosuppression early after lung transplantation was demonstrated to be efficacious and safe. Clinical trials registry: ClinicalTrials.gov NCT01404325.
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| Eligibility criteria
The study population comprised adults (>18 years) who had received a lung transplant from a deceased donor 3-18 months prior to study entry. All patients were required to have mild-or-moderate renal impairment, defined as eGFR ≥50 and ≤90 mL/min per 1.73 m 2 (CKD-EPI), prior to inclusion confirmed by 1 measurement prior to screening (maximum 42 days), a second measurement at screening, and a third measurement at baseline (ie, the randomization visit). Any 1 of these 3 measurements in the range ≥50 and ≤90 mL/min per 1.73 m 2 qualified patients for study entry. All 3 measurements had to be in the range ≥40 and ≤100 mL/min per 1.73 m 2 .
Patients were also required to be receiving CNI therapy, a cell cycle inhibitor, and steroids at the time of randomization. Key exclusion criteria were bronchiolitis obliterans syndrome (BOS) grade >1 at time of randomization, ≥2 episodes of antibody-treated acute rejection or ≥1 steroid-sensitive episode of acute rejection in the 3 months prior to randomization, urinary protein excretion >1 g/24 hours at randomization, a history of thrombotic microangiopathy, and significant cytopenia, as per protocol-specified definitions (see Table S1 for detailed exclusion criteria).
| Randomization and treatment
Randomization (1:1 ratio) was performed centrally. The randomization list was produced by an independent statistician not otherwise involved in the study using a validated system that automated the random assignment of treatment arms to randomization numbers in the specified ratio. given from randomization to the end of the study (Figure 1 ).
In patients randomized to the standard triple CNI arm, triple immunosuppression was continued as per center practice, with either a tacrolimus trough concentration >5 ng/mL or a CsA trough concentration ≥100 ng/mL (≥50 ng/mL at 2 years posttransplant), with MMF, EC-MPS, or azathioprine without specified doses and steroids (prednisone equivalent ≤0.2 mg/kg).
Prophylactic treatment for CMV was at the discretion of the investigator. Lifelong prophylactic treatment for Pneumocystis carinii pneumonia with trimethoprim/sulfamethoxazole was recommended; aerosolized pentamidine or dapsone could be administered to patients unable to tolerate oral trimethoprim/sulfamethoxazole.
| Evaluation and definitions
The primary endpoint was renal function at month 12 after randomization, as assessed by GFR estimated by the CKD-EPI formula. 24 Secondary endpoints are shown in decline of forced expiratory volume in 1 second (FEV 1 ) below 81% of baseline. 25 Acute rejection was defined as the presence of at least 1 symptom (dyspnea, fever, or malaise) or finding (infiltrates, decrease of FEV 1 ≥10% compared to previous measurement, pleural effusion, biopsy ≥A0) combined with exclusion of new infective agents and reversibility by rescue immunosuppression. When diagnosing acute rejection, other possible causes of pulmonary dysfunction such as infections had to be excluded and reversibility in response to standard treatment had to be proven. Biopsy-proven acute rejection (BPAR) was defined as acute rejection with biopsy grade >A0. Treatment-emergent adverse events are reported, ie, adverse events that started at the date of randomization or subsequently, up to the end of the study period (excluding events occurring ≥7 days after study drug discontinuation). Where no new causative organism was identified in cases of infection, the source was reported as "not specified." CMV infection as an adverse event was defined at the discretion of the investigator.
| Statistical analysis
A sample size of 116 randomized patients in each group, allowing for a dropout rate of 20%, was calculated to have 80% power to detect a difference in mean eGFR of 7 mL/min per 1.73 m 2 between groups at month 12 based on a SD of 15 mL/min per 1.73 m 2 and using a t test with a 5% 2-sided significance level. A difference of 7 mL/min per 1.73 m 2 was considered appropriate based on evidence from the Nordic Certican Trial in Heart and Lung Transplantation (NOCTET) study, 22 allowing for the shorter time from transplantation expected in the current trial compared to that in the NOCTET study population. 22 Due to slow recruitment, enrollment was stopped in December 2015 when 130 patients had been randomized. Post hoc, the power to detect a between-group difference for the primary endpoint was calculated to be 62%. No interim analysis was performed at that time point.
The primary endpoint was evaluated using analysis of covariance (ANCOVA) with treatment and center as factors, and eGFR at randomization as covariate. Unadjusted values and adjusted means (least square [LS] means) are presented with 2-sided 95% confidence intervals (CIs) and a 2-sided P value. If a patient discontinued from the study prematurely after randomization, missing data were imputed via a multiple imputation procedure. As a sensitivity analysis, the primary analysis was repeated (1) 
| Role of the funding source
The funders of the study (Novartis Pharma GmbH) contributed to the study design and coordinated data collection, and reviewed drafts of the manuscript for factual accuracy. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
| RE SULTS
| Study population
Of the 180 screened patients, 130 were randomized ( Figure 2 ).
Sixty-seven patients were randomized to the quadruple low CNI 
| Immunosuppression
In the quadruple low CNI group, the mean (SD) everolimus level was 4.2 In the standard triple CNI group, 45 patients were receiving tacrolimus and 18 patients were receiving CsA at randomization. The mean tacrolimus level was ≈10 ng/mL throughout the study ( Figure S1B ), with between 98% and 100% of patients above the minimum target threshold at any given study visit. The mean CsA level was ≈105 ng/mL ( Figure S1C) , with 50%-77% of the patients above the minimum target threshold at any given study visit. In the standard triple CNI group, 68 patients (92%) received MMF. The mean (SD)
dose of MMF from month 1 to the end of the study was 1472 (666)
| Renal function
The primary endpoint, adjusted mean of eGFR at month 12 pos- . A significant between-group difference was also seen when the analysis was confirmed using the LOCF method or in the per protocol population ( Table 2 ).
In the standard triple CNI group there was a gradual decrease in eGFR over the 12 months after randomization (Figure 3 ). In contrast, mean eGFR increased in the quadruple low CNI group within the first week after randomization, becoming significantly higher than in the Table 2, Table S3 ).
In a post hoc analysis, the primary endpoint was calculated ac- Mean (SD) total protein at month 12 was similar in both treatment groups: 66.8 (5.0) g/L in the quadruple low CNI group and 66.9 (4.6) g/L in the standard triple CNI group. New-onset proteinuria was not reported for patients in the quadruple low CNI group, and for 1 patient in the standard triple CNI group.
| Immunosuppressive efficacy
By month 12, 10 patients had experienced 11 episodes of clinically suspected acute rejection during treatment in each group (P = .811), including 6 episodes of BPAR (n = 5 grade A1, n = 1 grade A2) in the quadruple low CNI group and 4 episodes of BPAR (all grade A1) in the standard triple CNI group (P = .670). In total, 45 and 41 biopsies (P = .738) were performed in the quadruple low CNI and standard triple CNI groups. The majority of biopsy results (77% in the quadruple low CNI group, 76% in the standard triple CNI group) were A0, similar in both groups (P = .956). New-onset CLAD developed in 5 patients (7%) in the quadruple low CNI group and 9 patients in the standard triple CNI group (14%) by month 12 (P = .197).
TA B L E 1 Baseline characteristics (ITT/safety population)
Quadruple low CNI (N = 67) Standard triple CNI (N = 63)
One patient in each group died due to CLAD (log rank P = .897).
Two additional patients died in the quadruple low CNI group, due to septic shock (day 239) and hemorrhagic shock (day 209). There was no difference in mortality between the groups (log rank P = .251). All deaths occurred >30 days after study drug discontinuation.
| Exercise capacity and quality of life
The mean (SD) distance in the 6-minute walk test in the quadruple low CNI group and standard triple CNI groups, respectively, was 475 At month 12, the mean (SD) physical component summary score of the SF-36 was 47.2 (8.8) vs 47.7 (7.1) in the quadruple low CNI and standard triple CNI groups, respectively (P = .734), while the mean (SD) mental component summary score was 49.7 (11.8) vs 53.8 (9.1) (P = .032).
| Safety
Almost all patients experienced at least 1 adverse event (quadruple low CNI 99%, standard triple CNI 97%; P = .611), with acne (P = .002) and peripheral edema (P = .027) occurring more frequently in the quadruple low CNI arm (Table 3) . Adverse events with a suspected relation to study drug occurred in 47 patients (70%) in the quadruple low CNI group and in 40 patients (64%) in the standard triple CNI group (P = .459), with acne again more frequent in the quadruple low CNI group (P = .009) ( Infectious episodes occurred in 44 patients in the quadruple low CNI group (66%) and in 46 patients (73%) in the standard triple CNI group. Of the 153 infectious episodes reported, the source organism was determined in 79 cases, the most frequent being viral infections (Table 3 ). The most commonly reported infections were nasopharyngitis (25% and 27% of the patients in the quadruple low CNI group and standard triple CNI groups, respectively), CMV infection (15% and 22%), respiratory tract infection (13% and 13%), pneumonia (8% and 5%), and urinary tract infection (6% and 5%). CMV was reported as a serious adverse event in 1 patient in the quadruple low CNI group and in 3 patients in the standard triple CNI group, while pneumonia was reported as a serious adverse event in 3 patients in each group. BK virus infection was newly detected in 1 patient in the standard triple CNI group and no patient in the quadruple low CNI group.
There were more new or prolonged hospitalization episodes in the quadruple low CNI group, but these occurred in a comparable proportion of patients in both groups (Table 3) .
| D ISCUSS I ON
In this randomized trial, renal function at 1 year was significantly higher in maintenance lung transplant patients who were converted to detect survival differences or the incidence of end-stage kidney disease, the difference in kidney function based on these large epidemiological studies may be regarded as clinically significant.
The study selectively recruited patients with mild-or-moderate renal dysfunction, since the potential to improve renal function was considered necessary to justify conversion to the quadruple regimen.
The most marked benefit, however, was observed in the subpopulation with baseline eGFR in the range 40-60 mL/min per 1.73 m 2 .
Most previous randomized trials of everolimus with reduced CNI exposure initiated early after lung transplantation did not specify criteria for renal function at study entry, and no advantage for kidney function was noted for everolimus-based immunosuppression. 15, 21 In the randomized NOCTET study, a small improvement in measured GFR using everolimus with reduced CNI was observed after 1 and 2 years in long-term thoracic transplant patients. 22, 23 In that trial, patients were required to have a minimal baseline measured GFR of 20 mL/min, and the mean baseline eGFR was only 43 mL/min per 1.73 m 2 in the cohort of lung transplant recipients 22 compared to 65 mL/min per 1.73 m 2 in the quadruple low CNI cohort of our study.
In the current trial the quadruple low CNI patients were included much earlier, at an average of 10.8 months after lung transplantation, in contrast to 52 months in the NOCTET trial. This window seems appropriate to minimize the time-dependent development of irreversible CNI-related kidney damage.
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The everolimus target range (3-5 ng/mL) in the 4EVERLUNG trial was lower than in other recent trials of lung transplant recipients, most of which used a range of 3-8 ng/mL. 15, 22 In contrast to all but the NOCTET study, the everolimus group received quadruple therapy, including a cell cycle inhibitor (almost always MMF) and steroids to ensure immunosuppressive efficacy with reduced CNI exposure with limited side effects. This was confirmed by the fact that adverse events were similar to those with standard triple therapy within 12 months of treatment.
The incidence and severity of acute rejection showed no relevant differences between treatment groups in our trial. Third, direct measurement of GFR is ideal but challenging in daily practice, so GFR was estimated using the CKD-EPI equation, which is considered appropriate in the setting of lung transplantation. 34 GFR formulae for estimation may have limitations in overweight or underweight patients. Lastly, it should be stressed that the study selected patients with baseline eGFR in the range 50-90 mL/min per 1.73 m 2 , and who were 3-18 months posttransplant, and these findings cannot necessarily be extrapolated to other types of patients.
In conclusion, despite being underpowered, this randomized trial demonstrated that renal function in lung transplant patients was significantly higher 1 year after early conversion to everolimus with reduced CNI exposure than with standard triple CNI therapy.
Immunosuppressive efficacy was comparable using these regimens, both of which included MPA (or azathioprine) and steroids. Based on these findings, introduction of everolimus to support reduced CNI exposure can be considered in lung transplant patients with mild-tomoderate renal dysfunction.
